KR20170112750A - Cosmetic composition for improving acne containing propolis spicule powder - Google Patents
Cosmetic composition for improving acne containing propolis spicule powder Download PDFInfo
- Publication number
- KR20170112750A KR20170112750A KR1020160040293A KR20160040293A KR20170112750A KR 20170112750 A KR20170112750 A KR 20170112750A KR 1020160040293 A KR1020160040293 A KR 1020160040293A KR 20160040293 A KR20160040293 A KR 20160040293A KR 20170112750 A KR20170112750 A KR 20170112750A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- skin
- weight
- powder
- propolis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 27
- 241000241413 Propolis Species 0.000 title claims abstract description 25
- 229940069949 propolis Drugs 0.000 title claims abstract description 25
- 239000002537 cosmetic Substances 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 24
- 208000002874 Acne Vulgaris Diseases 0.000 title claims description 22
- 206010000496 acne Diseases 0.000 title claims description 22
- 239000000284 extract Substances 0.000 claims abstract description 84
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 14
- 229940109850 royal jelly Drugs 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 230000006872 improvement Effects 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 15
- 238000002137 ultrasound extraction Methods 0.000 claims description 14
- 241000243142 Porifera Species 0.000 claims description 13
- 235000016709 nutrition Nutrition 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 239000010931 gold Substances 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000004902 Softening Agent Substances 0.000 claims description 3
- 241000243172 Spongilla Species 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- -1 pack Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 49
- 230000000694 effects Effects 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000000605 extraction Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000257303 Hymenoptera Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000243175 Spongilla lacustris Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- 238000000608 laser ablation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000001117 malignant triton tumor Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241001442110 Ephydatia fluviatilis Species 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040840 Skin erosion Diseases 0.000 description 1
- 241000243169 Spongillidae Species 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005097 cold rolling Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
프로폴리스 추출물, 로얄젤리 추출물, 황금 추출물, 및 홍삼 추출물로 구성된 복합 추출물; 및 미세침 분말을 유효성분으로 포함하는 화장료 조성물이 제공된다. Complex extract consisting of propolis extract, royal jelly extract, golden extract, and red ginseng extract; And a fine needle powder as an active ingredient.
Description
본 발명은 천연 추출물 및 미세침 분말을 함유하는 여드름 개선용 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition for improving acne containing a natural extract and fine needle powder.
피부는 외부환경으로부터 생체를 보호하는 하는 기관으로서 인체 내의 물이나 전해질 등 생체성분의 손실을 방지하는 동시에 외부로부터 유해물질이 인체 내로 침입하지 못하도록 한다. 상기 피부는 크게 표피층, 진피층 및 피하지방층으로 구분된다. 상기 표피층은 각질세포와 멜라닌 세포로 구성되는데, 피부 최외곽의 각질세포층은 외부환경과 직접 접촉하기 때문에 물리적, 화학적 혹은 물질의 투과에 대한 강한 저항성이 요구되며, 인체의 수분이 손실되는 것을 막아줌과 동시에 자체로도 적당한 수분을 보유하여 유연성을 유지할 필요가 있다. The skin is an organ that protects the living body from the external environment and prevents the loss of biological components such as water and electrolytes in the human body while preventing harmful substances from entering the human body from the outside. The skin is largely divided into a skin layer, a dermal layer and a subcutaneous fat layer. The skin layer is composed of keratinocytes and melanocytes. Since the keratinocytes in the outermost layer of the skin are in direct contact with the external environment, they are required to have strong resistance against physical, chemical, or material permeation, At the same time, it is necessary to maintain proper water content to maintain flexibility.
각질세포층에 존재하는 천연보습 인자(Natural Moisturizing Factor: NMF)는 친수성의 수분 보유능을 가지며, 피부의 보습에 중요한 역할을 담당한다. 정상적인 각질세포층은 수분량이 약 10 내지 30% 정도 유지될 때 피부가 매끄럽고 부드러우며, 신체 보호기능을 정상적으로 발휘한다. 하지만, 각질세포층의 수분량이 10% 이하가 되면 피부는 거칠어지고 신체의 보호기능을 상실하여 피부 노화현상이 일어난다. Natural Moisturizing Factor (NMF), which is present in the keratin layer, has hydrophilic water retention capacity and plays an important role in skin moisturization. The normal keratinocyte layer is smooth and soft when the water content is maintained at about 10 to 30%, and the body protection functions normally. However, when the moisture content of the keratinocyte layer is less than 10%, the skin becomes coarse, the protective function of the body is lost, and the skin aging phenomenon occurs.
건성 피부의 경우 각질세포의 결집력이 약화되어 피부표면으로부터 비늘조각과 같이 벗겨져 나오는 스케일링현상이 나타나며, 이와 같은 피부의 건성화 현상은 각질세포충의 수분함량이 정상 피부 대비 감소할 때 발생한다. 또한, 건강한 피부라 할지라도 혹독한 외부요인 즉, 바람, 추운 날씨, 햇빛, 세안, 면도 등에 의해 수분 부족현상이 유발될 수 있으므로, 피부 각질세포층의 수분함량은 적절하게 유지되는 것이 바람직하다. In the case of dry skin, the keratinocyte aggregation is weakened and scaling phenomenon appears as peeled off from the surface of the skin. Such dryness of the skin occurs when the moisture content of the keratinocyte is reduced compared to the normal skin. In addition, even a healthy skin may cause a water shortage phenomenon due to harsh external factors such as wind, cold weather, sunlight, cleansing, shaving, etc., so that the moisture content of the keratinocyte layer is desirably maintained appropriately.
이런 이유로 피지 유사 성분이나 NMF 성분 또는 폴리올과 같은 보습제 등이 화장품에 첨가된다. For this reason, moisturizing agents such as sebum-like components, NMF components or polyols are added to cosmetics.
수용성 폴리올로서 수산기(OH 기)가 3개 이상인 글리세린, 솔리톨 등은 뛰어난 보습력을 가지는 반면 끈적임으로 인하여 사용성이 미흡하며, 수산기(OH 기)가 2개인 프로필렌글리콜, 1,3-부틸렌글리콜 등은 피부에 대한 부작용을 유발할 수 있다. 또한, 다른 천연보습인자인 피롤리돈 카르복실산 나트륨(PCA-Na), 젖산나트륨(Sodium lactate), 요소 등은 전해성이 강해 화장료의 유화안정성을 저하시킬 수 있다. 아미노산, 콜라겐, 엘라스틴 등도 보습능력이 있으나 보습능력에 한계가 있다. Glycerin and solitol having three or more hydroxyl groups (OH groups) as the water-soluble polyol have excellent moisture resistance, but are insufficient in usability due to stickiness, and have a hydroxyl group (OH group) having two hydroxyl groups such as propylene glycol and 1,3-butylene glycol Can cause side effects to the skin. In addition, other natural moisturizing factors, such as sodium pyrrolidonecarboxylate (PCA-Na), sodium lactate, urea, etc., are highly electrolytic and may deteriorate emulsion stability of the cosmetic. Amino acids, collagen, and elastin also have moisturizing ability, but they have limited moisturizing ability.
한편, 여드름은 피부의 모낭에서 생기는 염증성 질환으로서 환자의 70-80%는 11-25세의 연령층에 집중되며, 예전에는 사춘기 청소년에 대해 특이적인 질환으로 여겨지곤 했지만 요즘에는 성인에게도 흔히 발생하는 피부질환의 하나이다. On the other hand, acne is an inflammatory disease that occurs in the hair follicles of the skin. 70-80% of the patients are concentrated in the age group of 11-25 years. In the past, they were considered to be specific diseases for adolescent adolescents. However, It is one of the diseases.
여드름은 피지 분비의 증가, 하이퍼케라토시스(hyperkeratosis)에 의한 모낭의 협착, 여드름 균의 증식, 염증 반응 등에 의해 증세가 발전할 수 있으며, 또한 여러 가지 메카니즘이 복합적으로 작용하여 악영향을 미칠 수 있다. 여드름은 과도한 피지 분비 억제와 염증의 완화를 통해서 치료될 수 있다. 따라서, 여드름의 원인이 되는 복합적인 원인을 제거함으로써 여드름의 발생을 효과적으로 억제할 수 있다. Acne can develop symptoms due to an increase in sebum secretion, hyperkeratosis-induced follicular stenosis, proliferation of acne bacterium, inflammatory reaction, etc., and various mechanisms may be combined and adversely affected . Acne can be treated through excessive suppression of sebum secretion and relief of inflammation. Therefore, the occurrence of acne can be effectively suppressed by eliminating a complex cause that causes acne.
통상적으로 여드름 발생의 주요 원인을 제거하고 여드름을 치료하기 위하여 경구제 또는 외용제 형태의 약제가 사용될 수 있다. In general, medicines in the form of oral or topical agents may be used to remove the major cause of acne and treat acne.
구체적으로, 항남성 호르몬제를 사용한 피지생성의 억제 방법, 스테로이드 호르몬 및 비스테로이드성 소염 진통제의 항염증 작용을 위한 레소치놀, 유황, 살리실산, 벤조일퍼옥사이드, 레티노익산, 이소트레티노인 등의 항균제, 및 각질박리제, 테트라사이클린, 에리스로마이신, 메크로사이클린 등의 항생물질에 의한 프로피오니박테리움 아크네균의 활성억제 방법 등이 있다. Specifically, the present invention relates to a method for inhibiting sebum production using antihistamines, an antimicrobial agent such as resorcinol, sulfur, salicylic acid, benzoyl peroxide, retinoic acid, and isotretinoin for antiinflammatory action of steroid hormones and nonsteroidal antiinflammatory agents, A method of inhibiting the activity of propionibacterium acnes by an antibiotic substance such as a keratolytic agent, tetracycline, erythromycin, and macrocycline.
그러나, 상기 여드름 치료 방법은 여드름 치료에 일정 부분 성과를 나타내고 있음에도 불구하고, 효과, 부작용, 및 사용성의 측면에서 일부 문제점을 나타낸다. However, despite the fact that the acne treatment method has shown some success in treating acne, it shows some problems in terms of effectiveness, side effects, and usability.
구체적으로, 호르몬제는 표피의 생장억제 등의 호르몬 남용 부작용을 유발하며, 레티노익산과 벤조일퍼옥사이드 등의 각질박리제는 피부 자극에 의한 접촉성 피부염을 유발할 수 있으며, 테트라사이클린 등 항생물질은 내성균 발생을 촉진하고 광과민성 작용의 요인이 될 수 있다. Specifically, hormones induce hormone abuse side effects such as inhibition of epidermal growth. Keratolytic agents such as retinoic acid and benzoyl peroxide can cause contact dermatitis due to skin irritation. Antibiotics such as tetracycline may cause resistant bacteria And may be a factor of photosensitizing action.
화장품 업계에서는 여러 화학물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 제품이 다수 개발되고 있다. 천연 재료는 피부에 부작용이 적을 뿐 아니라, 최근 천연 재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발가치가 증가하고 있다. 그러나, 통상의 방법으로 수득된 천연물 추출물을 함유하는 화장료 제품은 항균 및 항염 등의 기능성이 효과적으로 구현되지 아니하며, 추출물의 활성이 지속적으로 유지, 제어되지 않으므로 실용성이 높지 않았다.In the cosmetics industry, many products using natural products have been developed to reduce skin irritation caused by various chemical substances. In addition to low adverse effects on the skin, natural materials have recently increased their value as a raw material for cosmetics, as consumers' responses to cosmetics using natural materials have increased. However, the cosmetic product containing the natural product extract obtained by a conventional method is not practically effective because antibacterial and anti-inflammatory functions are not effectively achieved and the activity of the extract is not maintained and controlled continuously.
따라서, 여드름의 치료 및 개선을 위해 인체에 안전할 뿐만 아니라 피부 개선 효과가 우수한 천연 유래 화장료 제품의 개발 필요성이 꾸준히 대두되고 있있으며, 최근 화장품 업계에서 점차 트렌드로 자리잡고 있는 다기능성(multi-functional) 화장품 개발에 대한 관심이 증대되고 있다. Therefore, in order to treat and improve acne, it is necessary to develop a natural-derived cosmetic product which is not only safe to human body but also has excellent skin-improving effect, and has recently become a multi-functional ) Interest in the development of cosmetics is growing.
본 발명은 전술한 문제점을 해결하기 위해 안출된 것으로, 본 발명의 목적은 천연 재료를 유효성분으로 포함하여 생체 안전성이 우수하며, 항염 및 항균 활성 효과가 현저히 증대된 여드름 개선용 화장료 조성물을 제공하는 것이다. Disclosure of the Invention The present invention has been conceived to solve the above-mentioned problems, and an object of the present invention is to provide a cosmetic composition for improving acne, which comprises a natural material as an active ingredient and has excellent biocompatibility, will be.
본 발명의 일 측면에 따르면, 프로폴리스 추출물, 로얄젤리 추출물, 황금 추출물, 및 홍삼 추출물로 구성된 복합 추출물; 및 미세침 분말을 유효성분으로 포함하는 화장료 조성물이 제공된다. According to one aspect of the present invention, there is provided a combination extract comprising a propolis extract, a royal jelly extract, a golden extract, and a red ginseng extract; And a fine needle powder as an active ingredient.
일 실시예에 있어서, 상기 미세침 분말은 해면 동물에서 수득할 수 있다. In one embodiment, the micropowder powder may be obtained from a sponge animal.
일 실시예에 있어서, 상기 해면 동물은 스폰질라 라쿠스트리스(Spongilla lacustris)일 수 있다. In one embodiment, the sponge animal may be a Spongilla lacustris .
일 실시예에 있어서, 상기 분말의 입자 평균 길이는 60 내지 500 ㎛일 수 있다. In one embodiment, the average particle length of the powder may be from 60 to 500 탆.
일 실시예에 있어서, 상기 복합 추출물은 상기 프로폴리스 추출물 20 내지 50 중량부, 상기 로얄젤리 추출물 10 내지 25 중량부, 상기 황금 추출물 10 내지 20 중량부, 및 상기 홍삼 추출물 10 내지 20 중량부로 구성될 수 있다. In one embodiment, the combined extract comprises 20 to 50 parts by weight of the propolis extract, 10 to 25 parts by weight of the royal jelly extract, 10 to 20 parts by weight of the gold extract, and 10 to 20 parts by weight of the red ginseng extract .
일 실시예에 있어서, 조성물 전체 중량에 대하여 상기 복합 추출물은 1.0 내지 30.0 중량% 함유되고, 상기 미세침 분말은 0.1 내지 5.0 중량% 함유될 수 있다. In one embodiment, the complex extract may be contained in an amount of 1.0 to 30.0 wt% based on the total weight of the composition, and the micropowder powder may be contained in an amount of 0.1 to 5.0 wt%.
일 실시예에 있어서, 상기 프로폴리스 추출물은 초음파 추출 방식으로 수득될 수 있다. In one embodiment, the propolis extract may be obtained by an ultrasonic extraction method.
일 실시예에 있어서, 상기 조성물은 여드름 개선용 또는 피부 진정용일 수 있다. In one embodiment, the composition may be for acne improvement or skin cleansing.
일 실시예에 있어서, 유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있다. In one embodiment, it may be formulated into one or more selected from the group consisting of softening lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder .
본 발명에 따르면, 상기 화장료 조성물은 프로폴리스에 함유된 다량의 유효 성분을 포함하므로 항염 및 항균 효과가 우수하다According to the present invention, since the cosmetic composition contains a large amount of active ingredient contained in propolis, it has excellent anti-inflammatory and antibacterial effects
또한, 상기 화장료 조성물은 복합 추출물에 함유된 유효성분의 상승작용으로 인하여 피부 개선효과가 극대화될 수 있으며, 미세침 분말에 의해 피부 침투 효과가 현저히 개선될 수 있다. In addition, the cosmetic composition can maximize the effect of improving the skin due to the synergistic action of the active ingredient contained in the complex extract, and the skin penetration effect can be remarkably improved by the fine needle powder.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.It should be understood that the effects of the present invention are not limited to the effects described above, but include all effects that can be deduced from the description of the invention or the composition of the invention set forth in the claims.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.As used herein, the terminology used herein is intended to encompass all commonly used generic terms that may be considered while considering the functionality of the present invention, but this may vary depending upon the intent or circumstance of the skilled artisan, the emergence of new technology, and the like. Also, in certain cases, there may be a term selected arbitrarily by the applicant, in which case the meaning thereof will be described in detail in the description of the corresponding invention. Therefore, the term used in the present invention should be defined based on the meaning of the term, not on the name of a simple term, but on the entire contents of the present invention.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다. Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms such as those defined in commonly used dictionaries are to be interpreted as having a meaning consistent with the contextual meaning of the related art and are to be interpreted as either ideal or overly formal in the sense of the present application Do not.
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.The numerical range includes numerical values defined in the above range. All numerical limitations of all the maximum numerical values given throughout this specification include all lower numerical limitations as the lower numerical limitations are explicitly stated. All the minimum numerical limitations given throughout this specification include all higher numerical limitations as the higher numerical limitations are explicitly stated. All numerical limitations given throughout this specification will include any better numerical range within a broader numerical range, as narrower numerical limitations are explicitly stated.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, embodiments of the present invention will be described in detail, but it should be apparent that the present invention is not limited by the following examples.
본 발명의 일 측면에 따르면, 프로폴리스 추출물, 로얄젤리 추출물, 황금 추출물, 및 홍삼 추출물로 구성된 복합 추출물; 및 미세침 분말을 유효성분으로 포함하는 화장료 조성물이 제공된다. According to one aspect of the present invention, there is provided a combination extract comprising a propolis extract, a royal jelly extract, a golden extract, and a red ginseng extract; And a fine needle powder as an active ingredient.
상기 화장료 조성물은 상기 복합 추출물을 유효성분으로 포함하므로, 피부 보습 효과, 항균 및 항염 활성이 우수하며 여드름 개선 효과가 매우 뛰어나다. 특히, 상기 화장료 조성물은 상기 복합 추출물에 함유된 각 성분의 상승 효과로 인해 상기 단일 추출물을 개별적으로 함유하는 화장료 조성물과 비교하여 피부 개선 효과가 현저히 개선될 수 있다. Since the cosmetic composition contains the above-mentioned complex extract as an active ingredient, it has excellent skin moisturizing effect, antibacterial and anti-inflammatory activity, and has excellent acne improvement effect. In particular, the cosmetic composition of the present invention can remarkably improve the skin-improving effect as compared with a cosmetic composition containing the single extract individually because of the synergistic effect of each component contained in the complex extract.
또한, 상기 화장료 조성물은 미세침 분말을 포함하므로, 상기 복합 추출물의 유효 성분의 피부 내 침투율이 현저히 증대될 수 있다. In addition, since the cosmetic composition contains fine needle powder, penetration of the active ingredient into the skin can be significantly increased.
상기 미세침(Spicule)은 대개 유럽, 러시아 지역의 담수에서 서식하는 해면 동물에서 채취되는 다양한 미세침의 형태를 띈 칼슘과 실리케이트로 이루어진 복합 물질이고, 일반적으로 분말의 형태로 수득할 수 있다. Spicule is a composite material composed of calcium and silicate in the form of various fine needles taken from sponges living in fresh water in Europe and Russia, and can be generally obtained in the form of powder.
상기 미세침은 미세한 침상형 구조로서 피부층을 침투하여 미세 통로를 형성하므로 도포된 화장료 성분의 침투 효과가 현저히 증대될 수 있다. 또한, 상기 미세침은 인위적 상처 치유에 작용하는 콜라겐의 피부재생을 촉진하고 피부 조직 온도를 상승시켜 생체 활성을 증대시킬 수 있다. The fine needle-like structure penetrates the skin layer as a fine needle-like structure and forms a micro channel, so that the penetration effect of the applied cosmetic ingredient can be remarkably increased. In addition, the fine needle can promote skin regeneration of collagen which acts on an artificial wound healing, and increase the skin tissue temperature to increase bioactivity.
상기 미세침은 인체에 무해한 물질로서 피부에 접촉될 때 피부를 자극하여 미세한 기공을 형성하고 체내에서 용해되거나 배출될 수 있는 분말형 소재라면 특별히 제한되지 않는다. The fine needle is a harmless substance to the human body and is not particularly limited as long as it is a powdery material capable of stimulating the skin to form fine pores and dissolved or discharged in the body.
일 실시예에 있어서, 상기 미세침 분말은 해면 동물에서 수득할 수 있으며, 상기 해면 동물은 스폰질라 라쿠스트리스 엘(Spongilla lacustris L.), 스폰질라 프라길리스 레이디(Spongilla fragilis Leidy) 및 에피다티아 플루비아틸리스(Ephydatia fluviatilis) 종에 속하는 해면일 수 있다. In one embodiment, the micropowder powder can be obtained from a spongy animal, wherein the spongy animal is a Spongilla lacustris L. ), Spongilla fragile Leidy , and Ephydatia fluviatilis species.
상기 해면동물은 근육, 신경 또는 장기가 존재하지 않은 원시적인 해양 생물로 5000 여종 이상이 존재한다. 골편은 무척추 동물의 체내에 존재하는 바늘 모양을 가지는 골격의 기능을 하는 조직으로 주로 규산 및 탄산 칼슘을 주성분으로 한다. 상기 해면동물은 탄산칼슘 또는 규산을 주성분으로 하는 1축, 3축, 4축 또는 다축 골편을 포함할 수 있다. The sponge animal is a primitive marine creature with no muscle, nerves or organs, and more than 5,000 species are present. The skeleton is a tissue that functions as a needle-like skeleton existing in the body of invertebrate animals, and mainly contains silicic acid and calcium carbonate. The sponge animal may comprise uniaxial, triaxial, tetragonal or multiaxial bone fragments containing calcium carbonate or silicic acid as a major component.
상기 해면동물은 주황색이나 청록색 등 다양한 색의 스펀지(sponge) 형태로 주로 바다에 서식하나, 민물 해면동물도 존재한다.The sponge is sponge of various colors such as orange or cyan, and it lives mainly in the sea, but there is also a freshwater sponge.
상기 해면동물은 세포들이 응집된 상태로 조직의 시초 단계에 있는 생물이며 몸체는 스펀지 섬유소(sponge fibers), 체벽을 형성하는 골편(spicules) 및 골편에 결합된 세포군으로 이루어진다. 상기 골편의 주성분은 석회질, 규산 또는 실리카 등이고 크기는 100 ㎛ 내외이므로 현미경에 의해 관찰될 수 있다. The sponge animal is an organism that is in the initial stage of tissue in a state where cells are aggregated, and the body is composed of sponge fibers, spicules forming body wall, and cells bound to bone fragments. The main component of the bone fragments is calcite, silicic acid, silica or the like, and the size is about 100 탆 or so and can be observed by a microscope.
상기 골편은 피부 재생의 효과적 수단으로서, 다양한 병인의 과색소침착, 미세 주름, 일광에 의한 손상 및 표재성 흉터, 면포, 확대된 모공과 같은 시각적 안면 결함을 교정하기 위한 용도로 사용될 수 있다. 또한, 피부 상태를 개선하는 물리적 시술인 미세 피부 연마술 및 피부 연마술, 화학 박피술, CO2 레이저 박피술 및 어븀 레이저 박피술에 대한 천연의 대안적 접근법으로 활용되고 있다. The bone fragments can be used as an effective means of skin regeneration to correct visual facial defects such as hyperpigmentation of various etiologies, fine wrinkles, sun damage, superficial scars, cotton wool and enlarged pores. It is also being used as a natural alternative approach to microdermabrasion and skin erosion, chemical peeling, CO 2 laser ablation, and erbium laser ablation, which are physical procedures to improve skin conditions.
상기 골편은 피부층에 접촉되어 마찰될 때, 물리적으로 분리하여 각질세포 응집을 감소시키고, 각질층, 피지 플러그, 및 각질세포를 탈리시켜 피부의 재생을 촉진할 수 있다. When the bone fragments come into contact with and rub against the skin layer, they are physically separated to reduce keratinocyte aggregation, and the keratin layer, sebum plug, and keratinocytes can be desorbed to promote regeneration of the skin.
상기 미세침 분말의 입자 평균 길이는 60 내지 500 ㎛일 수 있다. 상기 입자 평균 길이가 60㎛ 미만이면 피부 내에 효과적으로 침투하여 기공을 형성할 수 없고, 500 ㎛이면 분산성이 저하되거나 피부에 대한 과도한 자극을 유발할 수 있다. The average particle length of the fine needle-like powder may be 60 to 500 탆. If the average particle length is less than 60 탆, it can not effectively penetrate into the skin to form pores. If it is 500 탆, the dispersibility may be lowered or excessive stimulation to the skin may occur.
한편, 상기 “추출물”은 용매와 추출재료를 특정 조건하에서 접촉시킴으로써 추출재료에 함유된 유효성분이 전이된 용매를 지칭하는 것으로, 천연물로부터 원료에 함유된 성분을 뽑아냄으로써 수득된 물질이라면, 추출 방법이나 성분의 종류와 무관하게 모두 포함할 수 있다. 예컨대, 물이나 유기용매를 이용하여 천연물로부터 용매에 용해되는 성분을 추출해 낸 것, 천연물의 특정 성분, 예컨대 오일과 같은 특정 성분만을 추출하여 얻어진 것 등을 모두 포함할 수 있다. On the other hand, the " extract " refers to a solvent in which an effective ingredient contained in an extraction material has been transferred by bringing a solvent and an extraction material into contact under specific conditions. If the material is obtained by extracting a component contained in a raw material from a natural product, Regardless of the kind of the component. For example, it may include a component obtained by extracting a component dissolved in a solvent from a natural product using water or an organic solvent, a specific component of a natural product such as a product obtained by extracting only a specific component such as oil, and the like.
상기 “프로폴리스(propolis)”는 꿀벌이 자신의 생존과 번식을 위해 여러 식물에서 뽑아낸 수지와 같은 물질에 자신의 침과 효소 등을 섞어서 만든 물질로서, 유기물 및 미네랄을 다량 함유하며, 미네랄, 비타민, 아미노산, 지방, 유기산, 플라보노이드 등은 세포대사에 중요한 역할을 한다. 상기 프로폴리스는 항암성, 화상 치유능, 습진, 아토피성 피부염 및 무좀 등과 같은 진균류에 의한 피부병 치유 효과, 탈모 억제 효과, 미용 효과, 세균성 치과적 질환에 대한 치유 효과가 보고되었으며, 그 외에도, 호르몬 자극 활동, 비타민 p의 작용에 의한 괴혈병 치료, 고혈압 환자의 혈압강하작용, 생체 호르몬의 균형 유지 등 다양한 효과가 규명된 바 있다. "Propolis" is a substance made by mixing bees with their own needles and enzymes in a resin-like material extracted from various plants for their survival and propagation. It contains a large amount of organic matter and minerals, and contains minerals, Vitamins, amino acids, fats, organic acids, and flavonoids play important roles in cell metabolism. The propolis has been reported to have a therapeutic effect on skin diseases, hair loss suppression effect, cosmetic effect and bacterial dental disease caused by fungi such as anticancer, burning ability, eczema, atopic dermatitis and athlete's foot, Stimulating activity, treatment of scurvy by the action of vitamin p, hypotensive effect of hypertensive patients, balance of biohormones, and so on.
상기 “로얄젤리”는 꿀벌 유충의 영양 섭취에 사용되는 꿀벌의 분비물로, 젊은 일벌의 머리 부분에 있는 인두선(咽頭腺)에서 분비되며, 단백질, 당질이 주요 구성으로서, 비타민 A, B1, B2 가 풍부하고 수분, 지질, 당질, 회분, 효소, 호르몬, 스테로이드 등을 함유한다. 로얄젤리는 피부에 도포시 피부 표면의 수분을 적당하게 유지시키고, 피부의 대사를 증가시켜 탄력을 개선시키며, 항염증 작용을 통해 피부 트러블을 예방하는 효과가 있는 것으로 알려져 있다. The "royal jelly" is a secretion of bees used for nutrition of bee larvae. It is secreted from the pharyngeal gland at the head of young worker bees. Protein and saccharides are the main constituents, and vitamin A, B1, B2 And it contains water, lipids, saccharides, ash, enzymes, hormones, steroids and the like. Royal jelly is known to have the effect of keeping the moisture of skin surface properly when applied to the skin, improving the elasticity of the skin by increasing the metabolism of the skin, and preventing skin troubles through anti-inflammatory action.
상기 “황금(Scutellaria baicalensis)”은 꿀풀과에 속하는 여러해살이 초본식물인 황금(Scutellaria baicalensis GEORGE)의 뿌리로 만든 약재를 지칭한다. 상기 황금은 일반적으로 산지의 풀밭에서 자라고 여러 대가 나와 포기로 자라고 털이 있으며 가지가 갈라진다. 원뿌리는 원뿔형이고 살이 황색이다. 한방에서 뿌리는 해열, 이뇨, 지사, 이담 및 소염제로 사용된다. 한편, 상기 황금에 함유된 플라보노이드의 일종인 바이칼린은 항산화, 항암, 항염증의 효과를 가진다고 알려져 있다.The " golden ( Scutellaria baicalensis "refers to a medicinal product made from the roots of Scutellaria baicalensis GEORGE, a perennial herbaceous plant belonging to the family Lamiaceae. The gold generally grows in the grasses of the mountain area and grows in several layers, with hairs, hairy branches, and branches. The roots are conical and yellow in color. The roots in one room are used as fever, diuretic, branch, ejaculatory, and anti-inflammatory. On the other hand, it is known that baicalin, a type of flavonoid contained in gold, has antioxidant, anti-cancer and anti-inflammatory effects.
상기 “홍삼”은 오가피과 인삼속 인삼종에 속하는 다년생 식물인 수삼(Panax ginseng C)을 수증기 또는 기타 수단을 이용하여 증숙한 것을 지칭하는 것으로, 인삼의 원산지, 종류 및 형태 등은 제한되지 아니한다. 홍삼은 담황갈색 혹은 담적갈색을 나타내는 외관상 차이뿐만 아니라 건조 과정에서 수분이 증발되어 단위당 생리활성물질의 함량이 매우 높은 특징이 있으며, 항암성분(진세노사이드), 암세포 독소활성 억제성분(파낙시트리올), 혈소판 응집억제성분(말톨), 비만 억제성분, 노화 억제성분 및 중금속 해독성분 등을 함유하는 것으로 알려져 있다. The above-mentioned "red ginseng" means that the perennial ginseng ( Panax ginseng C) belonging to the ginseng belonging to the genus Ginseng is cooked by steam or other means, and the origin, type and form of ginseng are not limited. Red ginseng is characterized not only by difference in appearance which shows pale yellowish brown color or light reddish brown color but also in that moisture is evaporated in the drying process and the content of physiologically active substance per unit is very high. The anti-cancer component (ginsenoside), the component inhibiting cancer cell toxin activity ), A platelet aggregation inhibiting component (maltol), an obesity inhibiting component, an aging inhibiting component, and a heavy metal detoxifying component.
이 때, 상기 복합 추출물은 상기 프로폴리스 추출물 20 내지 50 중량부, 상기 로얄젤리 추출물 10 내지 25 중량부, 상기 황금 추출물 10 내지 20 중량부, 및 상기 홍삼 추출물 10 내지 20 중량부로 구성될 수 있다. The complex extract may comprise 20 to 50 parts by weight of the propolis extract, 10 to 25 parts by weight of the royal jelly extract, 10 to 20 parts by weight of the gold extract, and 10 to 20 parts by weight of the red ginseng extract.
상기 복합 추출물은 혼합 비율의 편차가 큰 경우 각 추출물의 유효성분에서 유래한 피부 개선 효과가 적절하게 구현되지 않을 수 있으므로, 작업 환경 및 최종 산물의 품질을 고려하여 혼합비율을 적절하게 제어할 수 있다. 본 발명자들은 수천례의 실험 결과를 토대로 상기 원료의 최적 혼합 비율을 도출하고자 하였으며, 상기 혼합 추출물의 피부 개선 효과가 극대화될 수 있다. When the variation in the mixing ratio of the complex extract is large, the skin improvement effect derived from the active ingredient of each extract may not be suitably implemented, so that the mixing ratio can be appropriately controlled in consideration of the working environment and the quality of the final product . The inventors intend to derive the optimal mixing ratio of the raw materials on the basis of the results of thousands of experiments, and the skin improving effect of the mixed extract can be maximized.
일 실시예에 있어서, 조성물 전체 중량에 대하여 상기 복합 추출물은 1.0 내지 30.0 중량% 함유되고, 상기 미세침 분말은 0.1 내지 5.0 중량% 함유될 수 있다. In one embodiment, the complex extract may be contained in an amount of 1.0 to 30.0 wt% based on the total weight of the composition, and the micropowder powder may be contained in an amount of 0.1 to 5.0 wt%.
상기 복합 추출물은 함량이 1.0 중량% 미만이면 기대하는 효과를 얻기 어려울 수 있으며, 30.0 중량%를 초과이면 첨가량 대비 현저한 효과가 구현되지 않을 수 있을 뿐만 아니라, 상기 복합 추출물의 비중이 과도하게 높아지므로 화장료 제품 본연의 품질이 훼손될 수 있다. If the content of the complex extract is less than 1.0% by weight, it may be difficult to obtain an expected effect. If the content of the complex extract is more than 30.0% by weight, a remarkable effect may not be realized compared with the addition amount, The inherent quality of the product may be compromised.
또한, 상기 미세침 분말의 함량이 0.1 중량% 미만이면 피부 침투 개선 효과가 충분히 구현되지 않으며, 5.0 중량% 초과이면 피부 자극으로 인해 부작용이나 피부 트러블이 유발될 수 있다. If the content of the fine needle-like powder is less than 0.1% by weight, the effect of improving the penetration of the skin is not sufficiently realized. If the content is more than 5.0% by weight, side effects or skin troubles may be caused by skin irritation.
한편, 상기 추출 공정에서 사용되는 용매의 종류는 특별히 한정되지 않으며, 필요에 따라 다양한 용매를 사용할 수 있다. 또한, 상기 추출은 상기 용매를 사용하여 냉침, 온침, 가열 등 당해 기술 분야의 통상적인 방법이 사용될 수 있다. On the other hand, the kind of the solvent used in the extraction step is not particularly limited, and various solvents may be used as needed. In addition, the extraction can be carried out using a conventional method in the art such as cold-rolling, warming, heating, and the like using the solvent.
상기 추출물은 물, 탄소수 1 내지 4의 저급 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트 및 1,3-부틸렌 글리콜로 이루어진 군으로부터 선택된 하나 이상의 용매로 추출될 수 있고, 상기 알코올은 60 내지 90% 농도(v/v)의 에탄올일 수 있다. The extract may be extracted with water, at least one solvent selected from the group consisting of lower alcohols having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate and 1,3-butylene glycol, and the alcohol has a concentration of 60 to 90% (v / v) ethanol.
즉, 상기 원료에 포함된 유효 성분은 용매의 극성에 따라 추출 비율이 상이해질 수 있으며, 상기 에탄올은 천연 원료의 생리 활성 물질의 추출에 있어서 선택성이 뛰어나므로 상기 에탄올 추출에 의해 최적의 피부 개선 효과가 구현될 수 있다. That is, the extraction ratio may be different depending on the polarity of the solvent, and the ethanol is excellent in the selectivity in the extraction of the physiologically active substance of the natural raw material. Therefore, Can be implemented.
특히, 물과 에탄올은 극성이 상이하여, 각 극성에 따라 추출되는 유효성분이 서로 차이가 날 수 있으므로 최적의 피부 개선 효과가 구현될 수 있도록 상기 에탄올의 농도를 적절히 제어할 수 있다. 다만, 상기 에탄올은 농도가 90% 초과이면 적정한 수율이 구현되지 않을 수 있고, 농도가 60% 미만이면 피부 개선 효과를 나타내는 유효 성분이 충분하게 추출되지 않을 수 있으므로 상기 알코올의 농도를 상기 범위 내에서 적절히 조정할 수 있다. Particularly, the water and ethanol have different polarities, and the effective components extracted according to the respective polarities may be different from each other, so that the concentration of the ethanol can be appropriately controlled so that an optimum skin improving effect can be realized. However, if the concentration of ethanol is more than 90%, an adequate yield may not be realized. If the concentration is less than 60%, the effective ingredient showing skin improvement effect may not be extracted sufficiently. Therefore, Can be adjusted appropriately.
한편, 상기 프로폴리스 추출물은 초음파 추출 방식으로 추출될 수 있다. 상기 초음파 추출 방식은 통상적인 열수 추출, 실온 추출, 가온 추출과 비교하여 추출 수율이 높고 생산성이 우수하므로, 프로폴리스에 함유된 유효 성분을 효과적으로 추출할 수 있다. Meanwhile, the propolis extract can be extracted by an ultrasonic extraction method. Since the ultrasonic extraction method has a high extraction yield and excellent productivity as compared with conventional hot water extraction, room temperature extraction and warming extraction, effective components contained in propolis can be effectively extracted.
상기 초음파 추출은 추출 원료를 물, 부틸렌글라이콜, 프로필렌글라이콜, 에탄올 등에서 선택된 어느 하나 또는 하나 이상의 추출용매에 넣은 후, 초음파 추출기로 약 1 내지 12 시간 동안 추출하는 것을 의미한다. 상기 초음파 추출의 시간은 추출하고자 하는 시료의 양에 따라 상이해질 수 있으며, 추출 산물을 여과 또는 정제하는 과정을 거칠 수 있다.The ultrasonic extraction means that the extraction raw material is put in one or more extraction solvents selected from water, butylen glycol, propylene glycol, ethanol, and the like, and then extracted with an ultrasonic extraction device for about 1 to 12 hours. The time of the ultrasonic extraction may be different according to the amount of the sample to be extracted, and the extraction product may be filtered or purified.
일 실시예에 따르면, 상기 초음파 추출은 pH 10 내지 12에서 1차 추출한 후, pH 5 내지 7에서 2차 추출할 수 있다. According to one embodiment, the ultrasonic extraction can be firstly extracted at pH 10 to 12, and then secondarily extracted at pH 5 to 7.
구체적으로, 상기 초음파 추출은 프로폴리스 원괴를 분쇄한 후, 알코올 수용액에 현탁시키는 단계; pH를 10 내지 12로 제어하는 단계; 1차 초음파 추출하는 단계; pH를 5 내지 7로 제어하는 단계; 2차 초음파 추출하는 단계를 포함할 수 있다. Specifically, the ultrasonic extraction comprises: pulverizing the propolis raw material and suspending the propolis raw material in an alcohol aqueous solution; controlling the pH to 10 to 12; A first ultrasonic extraction step; controlling the pH to 5 to 7; And a second ultrasound extraction step.
상기 프로폴리스는 pH 10 내지 12에서 밀랍이 분해되어 효율적으로 유효성분이 추출될 수 있으며, pH 5 내지 7 조건에서 수용성 프로폴리스가 에탄올 수용액에 용해되므로 각 단계에서 pH를 적절히 조절하는 것이 바람직하다.The propolis can be efficiently extracted with the beeswax at a pH of 10 to 12, and the effective component can be efficiently extracted. Since the water-soluble propolis is dissolved in the aqueous ethanol solution under the condition of pH 5 to 7, it is preferable to adjust the pH appropriately at each step.
이 때, 상기 초음파의 주파수는 프로폴리스 원괴의 양이나 상태에 따라 적절히 조절할 수 있으며, 바람직하게는 10~100 kHz일 수 있다. At this time, the frequency of the ultrasonic waves can be appropriately adjusted according to the amount and condition of the propolis raw material, and may be preferably 10 to 100 kHz.
일 실시예에 있어서, 상기 조성물은 여드름 개선용 또는 피부 진정용일 수 있다. 상기 화장료 조성물은 함유된 상기 복합 추출물이 미세침에 의해 피부에 효과적으로 침투 및 작용하여 피부 개선 효과가 현저히 개선될 수 있다. In one embodiment, the composition may be for acne improvement or skin cleansing. The cosmetic composition may effectively penetrate and act on the skin due to the fine needle as a result of which the skin improving effect can be remarkably improved.
일 실시예에 따르면, 상기 조성물은 유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있다.According to one embodiment, the composition is formulated into one or more selected from the group consisting of softening agents, nutritional lotions, nutritional creams, massage creams, essences, eye creams, cleansing creams, cleansing foams, cleansing waters, packs, .
상기 화장료 조성물은 각각의 제형에 있어서 상기 필수성분 외에 제형의 종류 또는 사용 목적 등에 따라 본 발명에 따른 목적을 저해하지 않는 범위 내에서 다른 성분들이 적절히 배합될 수 있다.The cosmetic composition of the present invention may be appropriately blended with other ingredients within the range of not compromising the object of the present invention depending on the kind of the formulation or the purpose of use, in addition to the essential ingredients in each formulation.
또한, 상기 화장료 조성물은 최종 제품의 품질이나 기능에 따라 업계에서 통상적으로 사용되는 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉 쇄제, 킬레이트화제, 보존제, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 추가적으로 함유할 수 있다. In addition, the cosmetic composition may be a lipid, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, Surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, Any other ingredient used may also additionally contain adjuvants commonly used in the cosmetics or dermatological sciences.
다만, 상기 보조제 및 그 혼합 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 영향을 미치지 않도록 적절히 선택하는 것이 바람직하다. However, it is preferable that the adjuvant and the mixing ratio thereof are appropriately selected so as not to affect the preferable properties of the cosmetic composition according to the present invention.
이하 실시예를 통해, 본 발명을 더욱 상술하나 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.The present invention will be further described with reference to the following examples, but it should be apparent that the present invention is not limited by the following examples.
제조예Manufacturing example 1 - 추출물의 제조 1 - Preparation of extract
에탄올을 용매로 하여 로얄젤리 추출물, 황금 추출물, 및 홍삼 추출물을 각각 제조하였다. 상기 각 추출물은 각 원료를 80% 에탄올 2L로 2시간씩 2회 환류 추출하여 제조되었으며, 감압 농축 및 동결 건조하여 고형으로 수득되었다. Royal jelly extract, golden extract, and red ginseng extract were prepared using ethanol as a solvent. Each of the extracts was prepared by refluxing the respective ingredients twice with 2 liters of 80% ethanol for 2 hours, and was obtained as a solid by concentration under reduced pressure and lyophilization.
복합 추출물은 프로폴리스 추출물 50g, 로얄젤리 추출물 20g, 황금 추출물 20g, 및 홍삼 추출물 20g을 혼합하여 제조하였다. The combined extracts were prepared by mixing 50 g of propolis extract, 20 g of royal jelly extract, 20 g of golden extract, and 20 g of red ginseng extract.
또한, 프로폴리스 추출물은 2단의 초음파 추출 방식으로 제조하였다. 프로폴리스 원괴를 밀링 머신으로 분쇄한 후, 80% 알코올 수용액에 현탁시켜 현탁액을 제조하였다. 이어서, 알칼리를 첨가하여 pH를 11로 조정한 후 20℃를 유지하며, 70 kHz 초음파를 1차로 가하여 1차 초음파 추출을 수행하였다. 다음으로, 상기 1차 추출물에 산을 첨가하여 pH를 6으로 조정한 다음 70 kHz 초음파를 2차로 가하여 2차 초음파 추출을 수행하였으며, 상기 추출물은 여과 공정을 거친 후 감압 농축 및 동결 건조하여 고형으로 수득되었다. The propolis extract was prepared by a two-stage ultrasonic extraction method. The propolis raw material was pulverized by a milling machine and suspended in an 80% aqueous alcohol solution to prepare a suspension. Subsequently, alkali was added to adjust the pH to 11, and then 20 캜 was maintained. Primary ultrasonic extraction was performed by applying 70 kHz ultrasonic wave first. Next, acid was added to the first extract to adjust the pH to 6. Then, second ultrasonic extraction was performed by applying 70 kHz ultrasonic waves to the second extract. The extract was subjected to filtration and then concentrated under reduced pressure and lyophilized to give a solid ≪ / RTI >
제조예Manufacturing example 2 - 2 - 미세침Fine needle 분말 제조 Powder manufacturing
건조된 해면(Spongilla lacustris )에서 수득한 천연 스폰지 200g에 0.5N-수산화나트륨 용액을 800ml를 투입하여 초음파 공정으로 혼합 및 분쇄하였다. 교반 후 원심분리를 통해 불순물을 제거하고, 정제수로 700ml를 투입하여 가용성 불순물 및 수산화나트륨 용액을 제거하였다.Dried sponges ( Spongilla 800 g of a 0.5 N sodium hydroxide solution was added to 200 g of the natural sponge obtained in lacustris and mixed and pulverized by an ultrasonic process. After stirring, impurities were removed by centrifugation and 700 ml of purified water was added to remove soluble impurities and sodium hydroxide solution.
2%-L-아스코르빈산 용액 800ml로 미량의 수산화나트륨을 화학 반응으로 제거하고 과투입된 L-아스코르빈산 용액을 제거한 후 건조시켜 정제수가 제거된 미세침 분말을 수득하였다. A small amount of sodium hydroxide was removed by chemical reaction with 800 ml of a 2% -L-ascorbic acid solution, and then the charged L-ascorbic acid solution was removed, followed by drying to obtain fine needle powder from which purified water was removed.
제조예Manufacturing example 3 - 시료의 제조 3 - Preparation of sample
제조예 1 및 2에서 수득된 추출물 및 미세침 분말을 혼합하여 하기 표 1과 같이 화장료 시료를 제조하였다. 실시예는 복합 추출물 및 미세침 분말을 동시 적용하여 미세침 도입에 따른 피부 개선 효과를 검증하고자 하였다. The extracts obtained in Preparation Examples 1 and 2 and the fine needle powder were mixed to prepare a cosmetic sample as shown in Table 1 below. The results of this study are as follows: 1.
비교예 1 내지 5는 복합 추출물, 프로폴리스 추출물, 로얄젤리 추출물, 황금 추출물, 홍삼 추출물을 각각 도입하였다. In Comparative Examples 1 to 5, the complex extract, propolis extract, royal jelly extract, golden extract, and red ginseng extract were respectively introduced.
실험예Experimental Example 1: 세포 독성 평가 1: Assessment of cytotoxicity
실시예 및 비교예 1 내지 5에서 수득된 시료가 세포에 미치는 독성을 측정하였다. 상기 실시예 및 비교예 1 내지 5에서 수득된 시료를 정제수에 현탁하여 농도별(100, 50, 25 μg/mL)로 조성한 후, 하기의 방법을 통해 세포 생존율을 측정하였다.The toxicity of the samples obtained in Examples and Comparative Examples 1 to 5 to cells was measured. The samples obtained in the above-mentioned Examples and Comparative Examples 1 to 5 were suspended in purified water and prepared by concentration (100, 50, 25 μg / mL), and cell viability was measured by the following method.
세포 독성은 MTT{3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide} 시약을 이용하여 세포 생존율을 측정하는 모스만(Mosmann)의 방법을 변형하여 실시하였다.Cytotoxicity was performed by modifying the method of Mosmann to measure cell viability using MTT {3- (4,5-dimethylthiazol-2-yl) -2-5-diphenyltetrazolium bromide} reagent.
HDF(Human Dermal Fibroblast) 세포를 96-well 플레이트에 1×104 cells/well의 농도로 분주하여 37℃, 5 % CO2 에서 24 시간 동안 안정화시켰다. 실시예 및 비교예 1 내지 5에서 수득된 시료를 농도별로 처리하여 24 시간 동안 배양하였다. 배지를 제거한 후 MTT를 5 mg/mL 농도로 처리하여 2 시간 동안 배양하였다. DMSO(Dimethyl sulfoxide)를 100μL 씩 넣고, 10 분 동안 교반한 후 540 nm에서 흡광도를 측정하였다.HDF (Human Dermal Fibroblast) cells were seeded in a 96-well plate at a concentration of 1 × 10 4 cells / well and stabilized at 37 ° C and 5% CO 2 for 24 hours. The samples obtained in Examples and Comparative Examples 1 to 5 were treated for each concentration and cultured for 24 hours. After the medium was removed, MTT was treated at a concentration of 5 mg / mL and cultured for 2 hours. 100 μL of DMSO (dimethyl sulfoxide) was added, stirred for 10 minutes, and absorbance was measured at 540 nm.
측정 결과, 각 시료의 모든 농도에서 세포 독성은 나타나지 않았다. 상기 결과는 상기 복합 추출물이 인체에 무해하며 안전성이 우수함을 시사한다. As a result of the measurement, no cytotoxicity was observed at all concentrations of each sample. The above results suggest that the combined extract is harmless to the human body and is excellent in safety.
실험예Experimental Example 2 : 피부 2: Skin 보습력Moisture power 개선 효과 평가 Evaluation of improvement effect
여드름이 있는 20~30대 성인 40명을 대상으로 1조당 20명씩 2개 조로 나누고, 상기 표 1의 제형화한 시료(영양크림)을 매일 2회씩 1개월간 얼굴 및 전반부에 도포하게 하였으며, 음성 대조군으로서 동일한 양의 정제수를 사용하였다. The sample (nutritional cream) shown in Table 1 was applied twice daily for 1 month to the face and the first half of 40 persons of 20 to 30 years old adults with acne, The same amount of purified water was used.
미리 도포 시작 전 항온, 항습 조건(온도 24℃, 습도 40%)에서 수분측정기(Corneometer, CM820 courage Khazaka electronic GmbH, Germany)를 이용하여 피부 전도도를 측정하고 기본 값으로 삼았으며, 2분 단위로 피부 전도도 증가율(%)을 측정하였다. The skin conductivity was measured using a moisture meter (Corneometer, CM820 courage Khazaka electronic GmbH, Germany) at a constant temperature and humidity condition (temperature 24 ° C., humidity 40%) before the start of application, The conductivity increase rate (%) was measured.
측정 결과, 실시예 1의 시료는 비교예 1 내지 5와 비교하여 피부 전도도 증가율이 우수한 것으로 나타났다. As a result of the measurement, the sample of Example 1 was found to have an excellent skin conductivity increase rate as compared with Comparative Examples 1 to 5.
일반적으로 피부 전도도는 피부 수분량에 비례하므로, 미세침 분말 및 복합 추출물을 함유하는 시료는 피부 내 수분의 이탈을 효과적으로 방지하여, 피부 보습력이 우수한 것으로 확인되었다. In general, the skin conductivity is proportional to the skin moisture content, so that the sample containing the fine needle powder and the complex extract effectively prevented the desorption of moisture in the skin and was excellent in skin moisturizing power.
실험예Experimental Example 3 : 여드름 개선 효과 평가 3: Evaluation of acne improvement effect
여드름을 가진 19~28세의 여성 중 50명에 대하여 제형화된 실시예 및 비교예 1 내지 5의 시료를 매일 2회씩 1개월간 얼굴 및 전반부에 도포하게 하였으며, 사용자의 의견에 따라 개선 정도를 판정하고 그 결과를 하기 표 3에 나타내었다. 50 of the women aged 19 to 28 with acne were applied to the face and the first half of the formulated example and the comparative examples 1 to 5 twice a day for one month. The results are shown in Table 3 below.
평가결과, 실시예 1의 시료(실시예)는 비교예 1 내지 5의 시료와 비교하여 여드름 개선 효과가 현저히 우수한 것으로 확인되었다. As a result of the evaluation, it was confirmed that the sample (Example) of Example 1 was remarkably excellent in the effect of improving acne as compared with the samples of Comparative Examples 1 to 5.
<평가기준><Evaluation Criteria>
+++: 매우 양호한 개선 효과가 있음 / ++: 상당한 개선 효과가 있음 / + : 약간의 개선 효과가 있음 / ± : 개선 효과는 없으나 악화되지도 않음 / -: 개선 효과 없고 오히려 약화됨+++: very good improvement effect / ++: considerable improvement effect / +: slight improvement effect / ±: no improvement effect but not deterioration / -: not improvement effect but rather weakness
실험예Experimental Example 4 : 아토피 피부염 개선 효과 4: Improvement of atopic dermatitis
급성 악화된 아토피 피부염 환자 100명을 대상으로 조를 나누고 실시예 및 비교예 1 내지 5의 시료를 사용하게 하였다. 사용 후 피부 건조증 개선 효과에 대한 설문조사를 시행하였다. 100 patients with acute exacerbated atopic dermatitis were divided into groups and samples of the Examples and Comparative Examples 1 to 5 were used. A questionnaire survey was conducted to evaluate the improvement of skin dryness after use.
도포 시에는 화장품 크림을 사용하듯 피부에 직접 상기 크림을 도포하였으며, 아토피 피부염 증상이 나타나는 부위에 상기 크림을 도포하였다. At the time of application, the cream was directly applied to the skin as using a cosmetic cream, and the cream was applied to a region where symptoms of atopic dermatitis appeared.
한 명의 동일한 검사자가 환자의 피부 병변의 호전 정도, SCORAD(SCORing Atopic Dermatitis) 점수를 평가하였고, 환자는 가려움증의 중증도를 평가하기 위한 시각적 아날로그 스케일(visual analogue scale, VAS, 0~10 cm)을 기록하였다. One identical examiner assessed the degree of improvement of skin lesion and SCORAD (scoring atopic dermatitis), and the patient scored a visual analogue scale (VAS, 0 ~ 10 cm) to assess the severity of itching Respectively.
평가는 시료 도포 후 1시간 이내에 이루어 졌으며, 그 결과를 하기 표 4에 나타내었다.The evaluation was made within one hour after application of the sample, and the results are shown in Table 4 below.
SCORAD 스코어가 40이상이면 아토피 증상이 심각한 것으로 평가된다. 실시예 1의 시료를 사용했을 때, SCORAD 스코어는 52.29에서 34.3으로 급격이 감소하여 아토피 상태가 현저히 호전되었다. If the SCORAD score is> 40, atopic symptoms are considered serious. When the sample of Example 1 was used, the SCORAD score decreased suddenly from 52.29 to 34.3, and the atopic state remarkably improved.
VAS 스코어는 10에 가까울수록 통증의 극심함을 의미한다. 실시예 1의 시료를 사용했을 때, VAS 스코어는 9점에서 3점으로 현저하게 감소하였으며, 아토피 피부염으로 인한 통증이 현저히 감소하였음을 시사한다.A VAS score of 10 means the severity of pain. When the sample of Example 1 was used, the VAS score was significantly reduced from 9 to 3, suggesting that pain due to atopic dermatitis was significantly reduced.
미세침 분말 및 복합 추출물을 함유하는 시료(실시예)는 피부에 도포될 때 미세침에 의해 복합 추출물이 피부 내에 효과적으로 침투하므로 체내 염증 반응, 가려움증을 수반하는 아토피 피부염 증상이 현저히 감소될 수 있다. The sample (Example) containing the fine needle powder and the complex extract effectively penetrates the complex extract into the skin due to the fine needle when applied to the skin, so that the symptoms of atopic dermatitis accompanying the inflammation reaction and itching can be significantly reduced.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. For example, each component described as a single entity may be distributed and implemented, and components described as being distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의해 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is defined by the appended claims, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included within the scope of the present invention.
Claims (9)
Complex extract consisting of propolis extract, royal jelly extract, golden extract, and red ginseng extract; And a fine needle powder as an active ingredient.
상기 미세침 분말은 해면 동물에서 수득한 화장료 조성물.
The method according to claim 1,
The fine needle powder is obtained from a sponge animal.
상기 해면 동물은 스폰질라 라쿠스트리스(Spongilla lacustris)인 화장료 조성물.
3. The method of claim 2,
The sponge animal is a Spongilla < RTI ID = 0.0 > lacustris .
상기 분말의 입자 평균 길이는 60 내지 500 ㎛인 화장료 조성물.
The method according to claim 1,
Wherein the powder has an average particle length of 60 to 500 占 퐉.
상기 복합 추출물은 상기 프로폴리스 추출물 20 내지 50 중량부, 상기 로얄젤리 추출물 10 내지 25 중량부, 상기 황금 추출물 10 내지 20 중량부, 및 상기 홍삼 추출물 10 내지 20 중량부로 구성된 화장료 조성물.
The method according to claim 1,
Wherein the complex extract comprises 20 to 50 parts by weight of the propolis extract, 10 to 25 parts by weight of the royal jelly extract, 10 to 20 parts by weight of the gold extract, and 10 to 20 parts by weight of the red ginseng extract.
조성물 전체 중량에 대하여 상기 복합 추출물은 1.0 내지 30.0 중량% 함유되고, 상기 미세침 분말은 0.1 내지 5.0 중량% 함유된 화장료 조성물.
The method according to claim 1,
Wherein the composite extract is contained in an amount of 1.0 to 30.0% by weight based on the total weight of the composition, and the fine needle powder is contained in an amount of 0.1 to 5.0% by weight.
상기 프로폴리스 추출물은 초음파 추출 방식으로 수득된 화장료 조성물.
The method according to claim 1,
The propolis extract is obtained by an ultrasonic extraction method.
여드름 개선용 또는 피부 진정용인 화장료 조성물.
8. The method according to any one of claims 1 to 7,
A cosmetic composition for acne improvement or skin soothing.
유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화된 화장료 조성물.8. The method according to any one of claims 1 to 7,
Wherein the cosmetic composition is formulated with at least one selected from the group consisting of softening agents, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160040293A KR101810231B1 (en) | 2016-04-01 | 2016-04-01 | Cosmetic composition for improving acne containing propolis spicule powder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160040293A KR101810231B1 (en) | 2016-04-01 | 2016-04-01 | Cosmetic composition for improving acne containing propolis spicule powder |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170112750A true KR20170112750A (en) | 2017-10-12 |
KR101810231B1 KR101810231B1 (en) | 2017-12-18 |
Family
ID=60141895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160040293A Expired - Fee Related KR101810231B1 (en) | 2016-04-01 | 2016-04-01 | Cosmetic composition for improving acne containing propolis spicule powder |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101810231B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101984260B1 (en) | 2018-11-08 | 2019-05-30 | 정재우 | Compositions for relieving joint or muscular pain including hydrolyzed sponges |
KR20190070556A (en) * | 2017-12-13 | 2019-06-21 | 이창하 | Face Cleansing Composition having Spicule |
KR20190070534A (en) * | 2017-12-13 | 2019-06-21 | 이창하 | Face Cleansing Composition having Spicule |
KR102130243B1 (en) * | 2019-02-08 | 2020-07-03 | 주식회사 엠디글로벌 | A cosmetic composition for skin whitening, anti-wrinkle, anti-aging, and anti-oxidation containing glutathione, natural spicule powder, acetyl hexapeptide and broussonetia kazinoki extract |
KR20230097290A (en) | 2021-12-23 | 2023-07-03 | 주식회사 앤드메이드 | Microneedle patch and method for helping lessening joint or muscular pain |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101884660B1 (en) * | 2018-05-18 | 2018-08-29 | 한국콜마주식회사 | Cosmetic composition containing the enzymatic extracts of natural substances comprising propolis, royal jelly and honey |
KR101933685B1 (en) | 2018-06-29 | 2018-12-28 | 주식회사 에스알바이오텍 | Drug Coated Microneedle and Manufacturing Method Thereof |
KR101969684B1 (en) * | 2018-11-15 | 2019-04-16 | 주식회사 엠디글로벌 | A cosmetic composition for anti-wrinkle and skin pore reduction containing natural spicule powder and natural complex extract |
KR102671694B1 (en) | 2022-10-19 | 2024-06-04 | 한국철도기술연구원 | Method for operating a power system using liquid hydrogen and fuel cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100937389B1 (en) * | 2009-01-23 | 2010-01-19 | (주)스킨메디언스 | Method for manufacturing cosmetics for improving the skin with cancellous bone grafts |
-
2016
- 2016-04-01 KR KR1020160040293A patent/KR101810231B1/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190070556A (en) * | 2017-12-13 | 2019-06-21 | 이창하 | Face Cleansing Composition having Spicule |
KR20190070534A (en) * | 2017-12-13 | 2019-06-21 | 이창하 | Face Cleansing Composition having Spicule |
KR101984260B1 (en) | 2018-11-08 | 2019-05-30 | 정재우 | Compositions for relieving joint or muscular pain including hydrolyzed sponges |
WO2020096127A1 (en) * | 2018-11-08 | 2020-05-14 | 정재우 | Composition comprising hydrolyzed sponge for relieving arthralgia or myalgia |
KR102130243B1 (en) * | 2019-02-08 | 2020-07-03 | 주식회사 엠디글로벌 | A cosmetic composition for skin whitening, anti-wrinkle, anti-aging, and anti-oxidation containing glutathione, natural spicule powder, acetyl hexapeptide and broussonetia kazinoki extract |
KR20230097290A (en) | 2021-12-23 | 2023-07-03 | 주식회사 앤드메이드 | Microneedle patch and method for helping lessening joint or muscular pain |
Also Published As
Publication number | Publication date |
---|---|
KR101810231B1 (en) | 2017-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101810231B1 (en) | Cosmetic composition for improving acne containing propolis spicule powder | |
KR101809266B1 (en) | Cosmetic composition containing propolis complex extracts | |
KR101860307B1 (en) | Cosmetic composition for moisturizing skin containing water-soluble silicon | |
KR101769419B1 (en) | Multifunctional nourishing cream composition and preparing method of the same | |
KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
CN108653013A (en) | A kind of plant moisturizing water profit after-sun frost and preparation method thereof | |
KR20200124986A (en) | Cosmetic composition comprising bamboo sprout peel extract | |
KR101055963B1 (en) | Cosmetic composition for promoting exfoliation | |
KR101810229B1 (en) | Cosmetic composition for improving acne containing teatree leaves spicule powder | |
CN112870116A (en) | Lip balm for moistening, preserving moisture and repairing lips, preparation method of lip balm, lip balm for moistening, preserving moisture and repairing lips and preparation method of lip balm | |
KR100513082B1 (en) | Cosmetic composition containing ceramide liposome with phyto complex extract and ceramide | |
KR20100006796A (en) | Anti-aging cosmetic composition comprising herb ferment extract | |
KR20090011682A (en) | Cosmetic composition for skin whitening containing the fruit berry extract as an active ingredient | |
CN108542829A (en) | A kind of plant moisturizing suncream and preparation method thereof | |
KR101969684B1 (en) | A cosmetic composition for anti-wrinkle and skin pore reduction containing natural spicule powder and natural complex extract | |
KR101862039B1 (en) | A cosmetic composition containing spicule powder and natural complex extract stabilized in nanoliposome | |
KR101854446B1 (en) | Cosmetic composition containing sageretia theezans extracts and spicule powder | |
KR102130243B1 (en) | A cosmetic composition for skin whitening, anti-wrinkle, anti-aging, and anti-oxidation containing glutathione, natural spicule powder, acetyl hexapeptide and broussonetia kazinoki extract | |
KR101896563B1 (en) | Cosmetic composition containing Ligustrum lucidum Aiton extract for moisturizing the skin | |
CN112716838A (en) | Rose essential oil eye repairing and tightening essence and preparation method thereof | |
KR102257448B1 (en) | Cosmetic composition containing black kelp | |
KR20150112103A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
KR100434898B1 (en) | Cosmetic composition containing medical plant complex extracts stabilized with liquid crystalsome | |
KR20160003918A (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
KR100667182B1 (en) | Cosmetics for improvement xeroderma containing badger oil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160401 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170522 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20171127 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20171212 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20171213 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20201207 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20211202 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20220920 Start annual number: 6 End annual number: 6 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20240923 |